Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Sonowal exhorted young researchers and scientist to work on evidence based scientific research
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
Subscribe To Our Newsletter & Stay Updated